当前位置：药药网 / 药品研发 / 美国药品上市后承诺数据库
LaViv, Azficel-T
申请企业
Fibrocell Technologies, Inc.
承诺描述
Conduct a study, based on a registry design, to assess the risk of skin cancer in the area of azficel-T injections and the risk of immune-mediated hypersensitivity reactions in 2700 patients who receive azficel-T.
承诺状态描述
The study completion date has passed, and the study has not yet been completed.